Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.
An exploratory pooled analysis indicates that the Lung Immune Prognostic Index score is associated with overall survival and progression-free survival in metastatic non-small-cell lung cancer patients receiving immune checkpoint inhibitors, targeted therapy, or cytotoxic chemotherapy.
Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.
Hurricane disasters significantly and adversely impact the overall survival of patients undergoing definitive radiotherapy for locally advanced non-small-cell lung cancer, study findings suggest.
Patients with non-small-cell lung cancer undergoing treatment with an EGFR–tyrosine kinase inhibitor may have a clinically meaningful risk for reactivation of unresolved hepatitis B virus infection during treatment, study findings indicate.
Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.
Researchers have identified key genomic alterations in brain metastases matched to primary non-small-cell lung cancer that could serve as prognostic markers and potential therapeutic targets.
Phase I study data suggest that ramucirumab plus pembrolizumab is a feasible treatment option for patients with previously treated advanced non-small-cell lung cancer, urothelial carcinoma, and gastric or gastroesophageal junction adenocarcinoma.
Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.
Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.
Results from two studies suggest that the current US Preventive Services Task Force lung cancer screening criteria may exclude certain individuals who could benefit from screening.
Poor outcomes among patients with non-small-cell lung cancer who receive corticosteroids prior to immunotherapy are driven by the use of steroids for palliative oncologic symptom management, study findings indicate.
Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.
Patients with locally advanced non-small-cell lung cancer have a high risk for major adverse cardiac events after radiotherapy that may warrant a reduction in cardiac radiation dose, study findings indicate.
Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.
Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.